Medicinehospital

Rituximab + Sodium Citrate Dihydrate + Sodium Chloride + Polysorbate -80 + Wfi

An antibody infusion (rituximab formulation) used for blood cancers and immune diseases.

Clinical information

Common uses

non-Hodgkin's lymphoma
chronic lymphocytic leukaemia
rheumatoid arthritis (with methotrexate)
vasculitis (GPA/MPA) and pemphigus vulgaris

Common side effects

infusion reactions
fever and chills
infections
low white blood cell counts
weakness

Cautions

severe, sometimes fatal infusion reactions — closely monitored (boxed warning)
can reactivate hepatitis B — screening required (boxed warning)
rare fatal brain infection (PML) reported (boxed warning)
severe skin and mouth reactions can occur (boxed warning)

Interactions

cisplatin — kidney damage risk
live vaccines — not recommended

Pregnancy: avoid — can affect the baby's immune cells; use contraception

Reference information, not medical advice — always follow your doctor or pharmacist. Source: DailyMed, dailymed.nlm.nih.gov, rituximab-arrx (Riabni) label, setid da1c4de7-0e5b-4f72-97ec-7a8d368f085f (accessed 2026-08-16)

Approved brands & formulations2

Brand name	Dosage form	Strength	Importer	Category
Rituximab + Sodium Citrate Dihydrate + Sodium Chloride + Polysorbate -80 + Wfi	Parenteral ( Injection )	500MG + 367.5MG+ 450.0MG + 35.0MG +QS TO 50.0ML in 10ML	MFDA designated importers with Pre Authorization approval before import	hospital
Rituximab + Sodium Citrate Dihydrate + Sodium Chloride + Polysorbate -80 + Wfi	Parenteral ( Injection )	100mg + 73.5mg + 90.0mg+7.0mg +QS to 10.0ml in 10ML	MFDA designated importers with Pre Authorization approval before import	hospital